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Abstract
Introduction Osteoporosis is a systemic skeletal disease
that is characterised by reduced bone strength and
increased fracture risk. Osteoporosis-related fractures
impose enormous disease and economic burden to
the society. Although many treatments and health
interventions are proven effective to prevent fractures,
health economic evaluation adds evidence to their
economic merits. Computer simulation modelling is a
useful approach to extrapolate clinical and economic
outcomes from clinical trials and it is increasingly used
in health economic evaluation. Many osteoporosis health
economic models have been developed in the past
decades; however, they are limited to academic use and
there are no publicly accessible health economic models
of osteoporosis.
Methods and analysis We will develop the Australian
osteoporosis health economic model based on our
previously published microsimulation model of
osteoporosis in the Chinese population. The development
of the model will follow the recommendations for the
conduct of economic evaluations in osteoporosis by the
European Society for Clinical and Economic Aspects of
Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
and the US branch of the International Osteoporosis
Foundation. The model will be a state-transition semiMarkov model with memory. Clinical parameters in
the model will be mainly obtained from the Dubbo
Osteoporosis Epidemiology Study and the health economic
parameters will be collected from the Australian arm of
the International Costs and Utilities Related to Osteoporotic
Fractures Study. Model transparency and validates will be
tested using the recommendations from Good Research
Practices in Modelling Task Forces. The model will be used
in economic evaluations of osteoporosis interventions
including pharmaceutical treatments and primary care
interventions. A user-friendly graphical user interface
will be developed, which will connect the user to the
calculation engine and the results will be generated. The
user interface will facilitate the use of our model by people
in different sectors.
Ethics and dissemination No ethical approval is
needed for this study. Results of the model validation and
future economic evaluation studies will be submitted to
journals. The user interface of the health economic model
will be publicly available online accompanied with a user
manual.

Strengths and limitations of this study
►► We will develop a state-transition microsimulation

for health economic evaluation of osteoporosis
interventions.
►► The model will be based on the Australian setting
and will be adapted and adaptable to other settings.
►► The model will be publicly available with a web interface to allow access for future users to evaluate
new osteoporosis interventions of interest in their
own settings.
►► The model will be developed following the consensus
statement endorsed by the Scientific Advisory Board
of Economic Aspects of Osteoporosis, Osteoarthritis
and Musculoskeletal Diseases, the Committee of
Scientific Advisors and the Committee of National
Societies of International Osteoporosis Foundation,
the US National Osteoporosis Foundation and
Osteoporosis Canada.

Introduction
Osteoporosis is a common disease that is
usually silent until a fracture occurs. Fracture is a global health concern particularly
in women. Australian women aged 60 years
were estimated to have a residual lifetime
fracture risk of 44% and the risk for Chinese
women was approximately 33%.1 2 Despite a
lower residual lifetime risk of having a fracture in men, the overall mortality HR in men
after a fracture was higher than women.3
For those who survived fractures, quality of
life (QoL) deteriorated dramatically up to
6 months after fracture and the loss of QoL
persisted in the remaining lifetime.4 With
an accelerated ageing global population,
the number of fractures will increase in the
coming decades.5 6
Bone strength is mainly reflected by bone
mineral density (BMD). Individuals with
reduced BMD are at the greatest risk of
osteoporotic fracture. The assessment of
fracture risk is largely based on clinical risk
factors with and without BMD.7 With the
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Objective
We aim to develop a publicly available health economic
model to evaluate the cost-effectiveness of osteoporosis
interventions. The model will be based on the Australian setting and will be adapted and adaptable to other
settings. Moreover, we will develop a web interface to
allow access for future users to evaluate new osteoporosis
interventions of interest in their own settings.
Methods and design
Model structure and parameters
We have published a microsimulation model of osteoporosis in the Chinese population and will develop the
Australian model using the existing model structure.18
The model will incorporate Australian fracture risk
equations for estimating absolute risk of osteoporosis
fractures based on patients’ characteristics (eg, age, sex,
family history, BMD, history of fractures and falls as well
2

Figure 1 Structure of the osteoporosis state-transition
model. Simulated patients transit in the model following the
arrow direction. Simulation is concluded when all simulated
patients transit to the ‘death’ state. Reprinted by permission
from Springer Nature Customer Service Centre GmbH:
Springer Nature.18

as comorbidities), and time-varying factors such as exposure to primary and/or secondary fracture prevention
therapy and patients’ accumulated history of fractures.
These equations will form the basis of the simulation
model for estimating outcomes for Australian patients
with osteoporosis.
The development of our osteoporosis health economic
model will follow the recently published modelling
guideline in osteoporosis.19 Simulations will be based
on a state-transition individual patient simulation model
(figure 1). Simulated patients in the model are either
alive or dead based on annual transitions. Outcomes will
be analysed over patients’ lifetimes but time horizons may
be varied according to the study of interest. Simulated
patients will transit in the model until they are absorbed
in the ‘death’ state.
Fragility facture is a key outcome of osteoporosis and
can occur in hip (proximal femur), vertebrae (spine),
wrist (distal radius) and other non-hip non-vertebral sites
such as humerus, pelvis, ribs and shoulder. Simulated
patients can have multiple fractures at different fracture
sites. Fracture probabilities will be simulated from one of
three risk engines. First, for countries that report fracture
incidence rates, fracture probabilities will be calculated
from incidence rates using the following equation:
( )
p = 1 − exp −r 

where p is the probability and r is the annual fracture
incidence rate by sex, fracture site and BMD level. In the
model for the Australian population, annual fracture
incidence rates by sex, fracture site and BMD level will
be obtained from the Dubbo Osteoporosis Epidemiology
Study.20 For countries without reported fracture incidence
rates, users will be able to choose the formula for calculation of annual fracture probabilities. Ten-year risk for
hip and all fragility fractures are predicted by the FRAX
or Garvan Fracture Risk Calculator (GARVAN-FRC).21–24
The annual probability of having a fracture will be calculated as:
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predicted fracture risk, treatment decisions can be made
following primary or secondary fracture prevention.8 9
Numerous therapeutic regimes, including pharmaceutical interventions, have been developed to treat osteoporotic patients by improving their BMD. While treatment
of osteoporosis has proven effective in preventing future
fractures, the associated cost must be considered against
the costs of not preventing fractures. In 2011/2012, the
Australian government spent over 179 million Australian dollars in pharmaceuticals for osteoporosis management.10 Similar costs of osteoporosis medications have
been noted elsewhere.6 11 12 With a range of osteoporosis
treatments available in the community, some governments employ health economic evaluation in treatment
reimbursement policy making, such as the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia
and the National Institute for Health and Care Excellence
(NICE) in the UK. These government agencies conduct
health economic evaluations of osteoporosis treatments
to select those that represent good value for money.
Health economic evaluation of osteoporosis interventions is commonly conducted using disease modelling
approaches,13 such as Markov cohort models and individual-level state-transition models.14–16 Health economic
modelling using different sources of information is able
to capture long-term cost and health benefits of osteoporosis interventions. Health economic analyses of osteoporosis interventions may be limited due to the validity,
transparency and accessibility of health economic models
that are used in the analyses. Making health economic
models transparent via thorough documentation and
making them available for public use are potential solutions to minimise these limitations; moreover, these solutions provide opportunities to update existing models with
newly available epidemiological and health economic data
as they become available.17 To date, there is no publicly
accessible health economic model of osteoporosis.

Open access
(
))
ln 1−P

t

p = 1 − exp


where P is the cumulative risk of having a fracture over
a period of t years. For example, for a given set of clinical risk factors, a group of patients is estimated to have
a 5% 10-year probability of having a hip fracture. In this
scenario, the annual probability of having a hip fracture
is calculated as 0.51%.
Simulated patients could stay without any fracture for
the entire life (represented as ‘no history of fracture’),
sustain a fracture (represented as ‘fractured’), stay in
postfracture state (represented as ‘postfracture’) or
sustain another fracture (represented as ‘fractured’). In
the case of death, Australian life tables combined with
fracture site-specific relative risks adjusted by time since
fracture will be used to calculate the probability of death
during the course of the simulation.3
The model will primarily take the societal perspective,
which is a broader perspective accounting for all stakeholders. In the Australian model, we will use data from
the Australian arm of the International Costs and Utilities
Related to Osteoporotic Fractures Study (AusICUROS)
to calculate the costs of direct health and non-healthcare utilisation.10 Specifically, direct healthcare utilisation
included hospitalisation, ambulance, imaging, medical
services, pharmaceuticals and supplements, non-admitted, subacute/rehabilitation and community-based
services including GP and physiotherapy services. Direct
non-healthcare utilisation included residential care, meals
on wheels and other community services.10 Relevant unit
costs of the above healthcare utilisation will be taken from
Pharmaceutical Benefit Scheme (PBS), Medical Benefit

Figure 2

Scheme (MBS) and other government reporting system
such as the Australian-refined diagnosis-related groups
(AR-DRGs). In addition, we will include indirect costs of
productivity loss. While societal perspective will be used
primarily, the cost data will be categorised to be adapted
for a different perspective for future use. For example,
when evaluating the cost-effectiveness of an osteoporosis
medication for listing on the PBS, only costs borne by the
Australian government will be included.
While the model can estimate the life expectancy, it will
primarily use quality-adjusted life years (QALYs) to quantify health outcomes, since this is the most commonly
used metric in health economic evaluations. The QALY,
which adjusts life expectancy by the degree of morbidity,
is usually measured on a health state utility (HSU) scale
where zero represents death and one represents full
health in each year of life. HSUs for each level of disease
severity will be incorporated from the AusICUROS and
an international meta-analysis of HSUV changes before
and after osteoporosis-related fractures.10 25
The overview of the osteoporosis model algorithm is
illustrated in figure 2.
Microsimulation
The Markov model is commonly used in chronic disease
modelling to facilitate the fact that patients can transit to
disease states repetitively during simulation. However, the
use of Markov modelling is limited to the Markov assumption, which relates to the fact that the future transitions
are not dependent on previous states.26 In osteoporosis
epidemiology, patients’ characteristics play an important
role in transition between disease states. For example, the
relative risk of having a subsequent fracture for patients

Overview of osteoporosis model algorithm. QALYs, quality-adjusted life years.
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Management with uncertainties and reporting uncertain
analyses
Four types of uncertainties are commonly considered in
health economic modelling studies, namely stochastic
uncertainty, parameter uncertainty, heterogeneity and
structural uncertainty.28 These uncertainities will be dealt
with during the development of the model and analyses.
For stochastic uncertainty, sufficient number of first-order
Monte Carlo simulations will be conducted. For parameter uncertainties, CI of parameters along with point estimates will be included in the model. For instance, gamma
or log normal distribution for cost data, log normal distribution for relative risks or hazard ratios will be used.29
Both deterministic and probabilistic sensitivity analyses
will be conducted to report uncertainties. One-way sensitivity analysis will be performed to evaluate how results
change by changing the value of individual parameters
and the results will be presented in tornado diagrams.
Probabilistic sensitivity analysis (PSA) will be conducted
by simultaneous sampling of all parameters that are
defined by distributions. Cost-effectiveness acceptability
curves (CEAC) and distribution of net monetary or net
health benefits will be presented to illustrate the cost-effectiveness decisions given a range of willingness-to-pay
(WTP) thresholds. Handling uncertainties and reporting
uncertainty analyses will be conducted in line with the
Good Research Practices in Modelling Task Force-6.28
Model transparency and validation
Cost-effectiveness of health interventions from modelling
studies informs policy decision makers when they prioritise funding for scarce healthcare resources. Therefore,
the validity and transparency of a health economic model
are keys in assisting policy decision making. Transparency of health economic models is subject to how well
the model is documented including its structure, parameters, equations and key assumptions used in the model.
Validity refers to how well the model represents the real
world.30 To ensure our model will be developed following
recommendations from the Good Research Practices in
Modelling Task Force-7,30 we will make the non-technical
documentation available following the example of the
previous work in diabetes from our team.31 There are
five aspects of validity, namely face validity, internal and
external validities, cross validity and predictive validity.30
4

In our study, we will primarily deal with face, internal and
external validities of our osteoporosis model.
For face validity, the clinicians in our team (JAE, TW,
JRC and AJP) will evaluate whether the model presents
the osteoporosis clinical pathway and the current osteoporosis management algorithms in Australia. For internal
and external validity, we will conduct goodness-of-fit analyses on the model results against values used in developing
the model (ie, internal validity) and that from literature
(external validity). In particular, we will compare the
following values: annual fracture rates by age and sex; life
expectancies by age and sex; residual lifetime fracture
risks by age, sex and BMD level. Goodness-of-fit analysis
will be conducted using linear regression. The slope of
the regression line along with the R-squared of the regression line and the root mean square error (RMSE) will be
used to assess the goodness-of-fit of the model predictions
and that from the literature.32 In addition, the Bland-Altman statistics will be reported to evaluate the agreement
between model results and real-world observed results.33
Patient and public involvement
Patients and public will not be involved in this study.

Application of the model
The first focus of the model application will be to quantify the cost-effectiveness of all first-line osteoporosis
secondary prevention fracture medications currently
reimbursed by the PBS in order to identify the most cost-effective medications and to further identify currently reimbursed medications that are not cost-effective indicating
the need for disinvestment in these medications.34The
second focus will be to identify the most cost-effective osteoporosis screening and treatment strategy in Australia, as
has been performed in China.35
The model will be used to evaluate the costs and incremental cost-effectiveness of alternative new interventions for primary and/or secondary fracture prevention.
Modelling is usually required in economic evaluations of
therapies for osteoporosis fracture prevention, as most
trials end before long-term outcomes are known.
Evaluating alternative management strategies will
comprise the following steps:
i. Development of the scenario to be simulated. This
involves choosing an intervention or management
guideline for evaluation. Evidence must be available
on its effect on fracture risks and synthesis undertaken to provide inputs for the simulation model. In the
case of this analysis, the intervention to be evaluated
may include denosumab, bisphosphonates and other
commonly used medical treatments presently available to confirm cost-effectiveness, or to identify for
disinvestment if no longer found to be cost-effective;
and any new medications not yet reimbursed under
the MBS.
ii. Simulating long-term outcomes and costs. This will
involve carrying out two simulations: in the first, the
Si L, et al. BMJ Open 2019;9:e028365. doi:10.1136/bmjopen-2018-028365
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with a prior fracture was higher and varied by sex, fracture site and BMD level.27 Likewise, mortality was also
higher after fracture.3 Therefore, we will use an individual-level state-transition model to incorporate the memory
of events occurring for simulated patients in the model.
Tracker variables will be used to record events of interest
during simulation. In our model, we will define the
following tracker variables to represent the heterogeneity
of simulated patients: ‘site of each fracture’, ‘number of
fracture by fracture site’, ‘time of the first fracture’, ‘time
since the last fracture’ and ‘time after treatment onset’.

Open access

Model interface and availability
We will capitalise on our team member AJP’s extensive
experience in his previous CORE Diabetes Model to
ensure similar successful translation of the model into
general use.36 A user-friendly graphical user interface will
be developed, which will connect the user to the calculation engine and the results are generated. Input data,
such as cohort characteristics, key cost and utility parameters, and key treatment characteristics (costs and effects)
will be accessible and editable by the user. They will be
stored in a structured query language (SQL) database.
Results generated by the model will also be written to and
stored in a database for easy future access by the user. A
user instruction manual and help files will be developed.
Like the CORE Diabetes Model, the osteoporosis model
will be made available to university or other public sector
research groups at no cost, while those seeking to use it
for commercial use (eg, such as pharmaceutical companies preparing a regulatory submission) will pay a license
fee that will support maintenance and further development of the web-based model.
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